StreetInsider.com News Articles

Form 3 Zhengye Biotechnology For: Jun 25 Filed by: Han Zhenfa

Thu, 25 Jun 2026 11:42:00 -0400

si-local-file:///var/storage/secattach/20260625/26690276.html

Form 3 Zhengye Biotechnology For: Jun 25 Filed by: Cheng Yuhong (nmn)

Thu, 25 Jun 2026 11:41:00 -0400

si-local-file:///var/storage/secattach/20260625/26690268.html

Form 3 Zhengye Biotechnology For: Jun 25 Filed by: Song Songlin

Thu, 25 Jun 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260625/26690259.html

Form 3 Zhengye Biotechnology For: Jun 25 Filed by: Jiang Ping (PiJi)

Thu, 25 Jun 2026 11:39:00 -0400

si-local-file:///var/storage/secattach/20260625/26690242.html

Form 3 Zhengye Biotechnology For: Jun 25 Filed by: Wang Ping (nmn)

Thu, 25 Jun 2026 11:39:00 -0400

si-local-file:///var/storage/secattach/20260625/26690251.html

Zhengye Biotechnology receives nasdaq deficiency notice

Thu, 04 Jun 2026 16:05:15 -0400

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) received a notification from Nasdaq on May 29 stating the company does not meet the minimum bid price requirement for continued listing.

The veterinary vaccine manufacturer's shares failed to maintain the required $1.00 minimum bid price for 30 consecutive business days from April 16 to May 28, according to the notification letter. Nasdaq Listing Rule 5550(a)(2) mandates listed securities maintain this minimum threshold.

The notification does not immediately impact the company's listing on the Nasdaq Capital Market. Zhengye has 180 calendar days until November 25 to regain compliance by achieving a closing bid price of at

Form 6-K Zhengye Biotechnology For: Jun 04

Thu, 04 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260604/26605571.html

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Thu, 04 Jun 2026 16:05:00 -0400

Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, announced that the Company had received a written notification letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on May 29, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules 5550(a)(2) for continued listing on the Nasdaq.

Nasdaq Listing

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Thu, 04 Jun 2026 16:05:00 -0400

Nasdaq Listing

Form 20-F Zhengye Biotechnology For: Dec 31

Tue, 28 Apr 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260428/26384686.html

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

Tue, 28 Apr 2026 16:30:00 -0400

JILIN, China, April 28, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2025.

Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2025 was a year of resilience for Zhengye. While the broader hog market experienced low and volatile price fluctuations and government macro-control policies contributed to near-term

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

Tue, 28 Apr 2026 16:30:00 -0400

Form 3 Zhengye Biotechnology For: Mar 24 Filed by: Li Guohan (nmn)

Fri, 24 Apr 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260424/26367713.html

Form 3 Zhengye Biotechnology For: Mar 24 Filed by: Hu Qiyi

Fri, 24 Apr 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260424/26367714.html

Zhengye Biotechnology implements dual-class share structure on NASDAQ

Mon, 06 Apr 2026 09:25:27 -0400

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) announced the implementation of a dual-class share structure effective April 7, 2026, according to a company statement.

Shareholders approved the introduction of Class A and Class B ordinary shares at the annual general meeting held March 24, 2026. The company's Class A ordinary shares began trading on the Nasdaq Capital Market under the existing ticker symbol "ZYBT."

Under the new structure, the company's authorized share capital of $50,000 is divided into 2 billion ordinary shares with a par value of $0.000025 each. This includes 1.9 billion Class A ordinary shares and 100 million Class B ordinary

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

Mon, 06 Apr 2026 09:25:00 -0400

Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced the implementation of a dual-class share structure, effective April 7, 2026.

At the annual general meeting of shareholders held on March 24, 2026, the Company’s shareholders approved the introduction of two classes of ordinary shares, designated as Class A and Class B. The Company’s Class A ordinary shares are expected to begin trading

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

Mon, 06 Apr 2026 09:25:00 -0400

Form 6-K Zhengye Biotechnology For: Mar 24

Wed, 25 Mar 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260325/26212668.html

Form 3 Zhengye Biotechnology For: Mar 18 Filed by: Han Aiden

Wed, 18 Mar 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260318/26184757.html

Form 3 Zhengye Biotechnology For: Mar 18 Filed by: Sun Wenhua

Wed, 18 Mar 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260318/26184763.html

Form 3 Zhengye Biotechnology For: Mar 18 Filed by: Lian Wei

Wed, 18 Mar 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260318/26184782.html

Form 3 Zhengye Biotechnology For: Mar 18 Filed by: Liu Zhongyao

Wed, 18 Mar 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260318/26184784.html

Form 6-K Zhengye Biotechnology For: Feb 27

Mon, 02 Mar 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260302/26086086.html

Form 6-K Zhengye Biotechnology For: Feb 23

Mon, 23 Feb 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260223/26043347.html

Zhengye Biotechnology releases 2026 chairman letter outlining growth plans

Tue, 10 Feb 2026 08:32:42 -0400

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) released a letter from Chairman Zhenfa Han detailing the company's achievements in 2025 and strategic priorities for 2026, according to a company statement.

The Chinese veterinary vaccine manufacturer secured four new patent grants in 2025 and received approval for two National Category I New Veterinary Drug Registration Certificates from China's Ministry of Agriculture and Rural Affairs. The company obtained seven new product approval licenses covering vaccines for swine, poultry, cattle, and sheep.

Zhengye completed its initial public offering and began trading on the Nasdaq Capital Market in January 2025 under ticker symbol ZYBT. The company established